Brief Communication: Lambert-Eaton Myasthenic Paraneoplastic Syndrome Associated With Merkel Cell Carcinoma Successfully Treated by Immune Checkpoint Inhibitors: 2 Cases
M. Gra(Centre Hospitalier Universitaire de Bordeaux), S. Prey(Centre Hospitalier Universitaire de Bordeaux), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), M. Beylot‐Barry, Louis Carla(Neurology, Inc), Fanny Duval, Anne Pham‐Ledard(Peter MacCallum Cancer Centre), E. Gérard(Université de Bordeaux), Antoine Soulages(Centre Hospitalier Universitaire de Bordeaux)
Cited by 2
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k